Showing 1179 results
- https://www.novartis.com/news/media-releases/novartis-erzielt-2017-eine-gute-operative-performance-sowie-wegweisende-innovationen-und-ist-gut-gerustet-fur-die-nachste-wachstumsphaseDer Umsatz steigt im Geschäftsjahr um 2% (kWk, +1% USD), wobei die starke Performance unserer Wachstumstreiber, wie Cosentyx und Entresto, die Einbussen durch Generika bei Glivec/Gleevec mehr als…
- https://www.novartis.com/news/media-releases/novartis-renews-commitment-malaria-elimination-investing-usd-100-million-research-and-develop-next-generation-antimalarialsCompany to invest more than USD 100 million to advance research and development of new antimalarials over the next five years Commitment includes expanding access to pediatric antimalarials and…
- https://www.novartis.com/news/media-releases/novartis-bekraftigt-engagement-zur-eliminierung-von-malaria-und-investiert-usd-100-millionen-die-erforschung-und-entwicklung-der-nachsten-generation-von-malariamedikamentenDas Unternehmen investiert in den kommenden fünf Jahren über USD 100 Millionen, um die Erforschung und Entwicklung neuer Malariamedikamente voranzutreiben Das Engagement beinhaltet einen Ausbau…
- https://www.novartis.com/news/media-releases/novartis-renouvelle-son-engagement-afin-deliminer-le-paludisme-en-investissant-100-millions-de-dollars-dans-la-recherche-et-le-developpement-dantipaludiques-de-nouvelle-generationL'entreprise s'apprête à investir plus de 100 millions de dollars afin de faire progresser la recherche et le développement de nouveaux antipaludiques au cours des cinq prochaines années L'…
- https://www.novartis.com/news/media-releases/novartis-tender-offer-avexis-commencesBasel, April 17, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that its indirect wholly-owned subsidiary, Novartis AM Merger Corporation, a Delaware corporation ("Purchaser"), has…
- https://www.novartis.com/news/media-releases/novartis-announces-new-analysis-demonstrating-entresto-helped-preserve-kidney-function-patients-chronic-heart-failure-especially-those-diabetesHeart failure (HF) patients with reduced ejection fraction treated with Entresto experienced significantly less reduction in kidney function compared to patients treated with standard of care ACE…
- https://www.novartis.com/news/media-releases/novartis-enters-agreement-acquire-avexis-inc-usd-87-bn-transform-care-sma-and-expand-position-gene-therapy-and-neuroscience-leaderAveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong…
- https://www.novartis.com/news/media-releases/novartis-schliesst-vereinbarung-zum-erwerb-von-avexis-inc-fur-usd-87-mrd-ab-um-therapie-der-sma-zu-transformieren-und-position-als-fuhrendes-gentherapie-und-neuroscience-unternehmen-auszubauenFührender Produktkandidat von AveXis, AVXS-101, hat das Potenzial, erste Genersatztherapie zur einmaligen Anwendung zur Behandlung der spinalen Muskelatrophie (SMA) zu werden eine…
- https://www.novartis.com/news/media-releases/sandoz-outlines-plans-next-healthcare-access-challenge-hack-support-local-digital-innovationSandoz White Paper outlines importance of digital solutions to specific local healthcare problems, as part of approach to increasing access to healthcare Publication, which coincides with World…
- https://www.novartis.com/news/media-releases/novartis-announces-jama-cardiology-publication-data-showing-entresto-improves-physical-and-social-activity-hfref-patients-versus-enalaprilPost-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 118
- › Next page